Abstract
Gemtuzumab ozogamicin (Mylotarg®) therapy may cause sinusoidal obstruction syndrome (SOS), the mechanism of which probably involves targeting of CD33+ cells in the sinusoids of the liver, activation of stellate cells, damage to sinusoidal endothelial cells, sinusoidal vasoconstriction, and ischemic hepatocyte necrosis. The clinical manifestations of this liver injury are hepatomegaly, weight gain, ascites, jaundice, and elevation of serum aminotransferase enzymes. An approach to patient management includes being certain that SOS is the correct diagnosis; ensuring that liver blood flow is optimized; and managing the accumulation of fluid in the peritoneal cavity, pleural spaces, and pulmonary interstitium. Currently, there is no specific therapy that is directed at the sinusoidal pathology caused by gemtuzumab ozogamicin. There are, however, several rational therapies that might be tried in patients who exhibit adverse prognostic signs early in the course of SOS. There is also considerable ongoing hepatology research dealing with stellate cell and sinusoidal endothelial cell biology and regulation of sinusoidal blood flow that can be brought to bear on this problem in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
